Compare Crispr Therapeutics AG (CRSP) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Crispr Therapeutics AG trades at $53.55 (market cap $4.88B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $42.16 (market cap $3.80B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days on average.
| CRSP | VNQI | |
|---|---|---|
Market Cap | $4.88B | $3.80B |
Volume | 2,861,747 | 277,049 |
Sector | Health | — |
52-Week High | $74.92 | $50.76 |
52-Week Low | $44.34 | $41.81 |
Typical Hold Time | 77 Days | 95 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
VNQI trades at $42.15, up 0.81% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF focuses on international real estate, offering diversification and a higher dividend yield than some peers, but key financial ratios are not disclosed in the provided data. Recent news highlights a significant drop in short interest and comparisons with competing real estate ETFs.
The outlook remains cautious due to weak technical momentum and global real estate market uncertainties. Opportunities include international diversification and income from dividends, but risks involve currency fluctuations, economic cycles abroad, and underperformance versus U.S. real estate. Investors should weigh the bearish technicals against long-term diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
